Breast Cancer Diagnosis: Who Do You See First and What Comes Next?
28:14
Baptist Health Cancer Care
Host: Johanna Gomez, award-winning host & journalist
Published: August 17, 2026
Host: Johanna Gomez, award-winning host & journalist
Published: August 17, 2026
After a breast cancer diagnosis, what happens first—seeing an oncologist, having surgery or starting chemotherapy? And how do doctors decide between a lumpectomy and a mastectomy? In this episode of Baptist Health Talk, host Johanna Gomez sits down with Dr. Mehran Habibi, Deputy Chief of Breast Surgery with Baptist Health Cancer Care, to answer common questions patients search online about breast cancer surgery and treatment.
They discuss:
- The difference between a medical oncologist and a surgical oncologist
- Who patients typically see first after a breast cancer diagnosis
- How doctors decide whether chemotherapy or surgery comes first
- Why chemo first does not automatically mean the cancer is more aggressive
- Whether chemotherapy can be shortened when a tumor responds well
- Why second opinions and breast cancer specialists can matter
- The truth about the myth that surgery or biopsy can make breast cancer spread
- Why treatment may still be needed after a tumor is removed
- How doctors and patients choose between lumpectomy and mastectomy
- Why feeling fine is not a reason to delay recommended treatment
- How lymph node involvement affects staging and treatment
- Options for immediate or delayed breast reconstruction
- How AI is beginning to support breast imaging, surgical planning and treatment decisions
Host: Johanna Gomez, award-winning host & journalist
Guest: Mehran Habibi, M.D., deputy chief of Breast Surgery, Baptist Health Cancer Care
Featured Provider
Mehran Habibi, MD
Mehran Habibi, M.D., MBA, is an internationally recognized surgical breast oncologist with over two decades of clinical and academic leadership. He serves as chief of breast surgery at Baptist Health Herbert Wertheim Cancer Institute and deputy chief of breast surgery for Baptist Health Cancer Care. His clinical expertise includes oncoplastic and nipple-sparing mastectomies, nerve-preserving and risk-reducing procedures, and advanced intraoperative tumor localization and margin assessment technologies.
Before joining Baptist Health, Dr. Habibi held senior leadership roles at Northwell Health, including director of breast surgery at Staten Island University Hospital, regional chief of breast surgery for Northwell’s Western Region and director of international program development for Northwell Cancer Institute. He also served as an associate professor of surgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Prior to that, he spent more than 15 years at Johns Hopkins University School of Medicine, where he founded and led the Breast Center at the Bayview Medical Center.
Dr. Habibi’s research program spans surgical innovation, genomics and tumor microenvironment studies. His current investigations include wire-free localization techniques, intraoperative margin assessment tools and studies of tumor tissue mechanics, breast cancer genomics, and the role of the microbiome in breast cancer progression and therapy response. His research has been supported by multiple grants and published in high-impact peer-reviewed journals.
Certified by the American Board of Surgery, Dr. Habibi is a fellow of the American Society of Breast Surgeons and a reviewer for The Breast Journal and JAMA Surgery. He is also an editorial board member of Archives of Breast Cancer.
Dr. Habibi earned his medical degree at Islamic Azad University in Tehran and completed surgical training at Pennsylvania Hospital and St. Luke’s Hospital. He completed a fellowship in complex surgical oncology at the Medical College of Virginia and holds a master’s degree in business administration from Virginia Commonwealth University.
Outside the operating room, Dr. Habibi is known for his love of photography, swimming and baking—where his pastry skills rival his surgical precision.
Compassionate, Expert Cancer Care at Baptist Health
Related Stories
View All Articles
FDA Approval of Daraxonrasib Signals a New Era in Pancreatic Cancer Treatment
August 28, 2026
5 min. read